KMB vs SUZ: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SUZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KMB and SUZ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KMB and SUZ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kimberly-Clark is a consumer staples company that makes and sells personal care and tissue products under household brand names. Its portfolio includes Huggies diapers, Pull-Ups training pants, Kotex feminine care, Depend and Poise adult incontinence products, Kleenex tissues, Cottonelle and Scott bath tissue, and Viva paper towels. The company organizes around Personal Care (its largest and most profitable business), Consumer Tissue, and a professional/away-from-home business serving offices, restaurants, and institutions (sold under the Kimberly-Clark Professional banner). Roughly half of revenue comes from outside North America, with meaningful exposure to developing and emerging markets where category penetration is still rising. Kimberly-Clark makes money by selling repeat-purchase, non-discretionary household essentials at scale, leaning on brand strength, retail distribution, and manufacturing efficiency. The business is a classic defensive staple: steady demand, modest organic growth, and a long dividend history. Headquartered in Irving, Texas, it has been a Dividend Aristocrat for decades.

Full KMB guide

Suzano grows eucalyptus in Brazil, converts it into bleached hardwood kraft pulp, and ships it to tissue, printing and specialty paper makers worldwide. Pulp is roughly ~75% of revenue and paper roughly ~25% in the most recent reporting period. The Cerrado mill at Ribas do Rio Pardo in Mato Grosso do Sul, which started up in mid-2024 at about ~2.55 million tonnes of annual capacity, is the largest single-line pulp mill ever built and took total capacity above ~11 million tonnes a year. The company also owns Portocel, the only dedicated pulp port terminal in Brazil, sells printing and writing brands including Report and Reciclato, runs Brazilian tissue lines, and has pushed downstream through the Pine Bluff, Arkansas paperboard mill acquired from Pactiv Evergreen, a 51% stake in Arbex, the global tissue company formed with Kimberly-Clark's international tissue and professional business (completed for ~US$1.3 billion in cash after June 2026), and a minority equity stake in the Austrian fibre maker Lenzing.

Full SUZ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KMB drivers: Defensive, repeat-purchase demand; Emerging-market category growth.
• SUZ drivers: Cost position on the fibre curve; Cerrado volume converting into cash.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Kimberly-Clark sells largely commoditized products where private-label store brands compete aggressively on price, capping pricing power and pressuring volumes when consumers trade down. For SUZ, suzano is a price taker in a commodity set in dollars per tonne, so a soft bleached hardwood kraft market compresses earnings no matter how well the mills run.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KMB if you believe its drivers more; SUZ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KMB and SUZ guides.

KMB. Kimberly-Clark trades at about 14 times forward earnings, a discount to its own history after a roughly 12% decline over the past year, and the dividend yield has climbed to about 4.9%. The trailing P/E near 21 is inflated by one-time items in GAAP earnings tied to its restructuring. The multiple remains sensitive to interest rates, and for the next few quarters also to how the market judges the Kenvue acquisition and its financing.

SUZ. A mid-single-digit earnings multiple on a company selling record pulp volumes means the market is pricing the cycle rather than the quarter, and trailing net income includes currency effects on dollar debt that do not repeat in a straight line. Gross debt of roughly ~R$99 billion against ~R$26 billion of cash leaves the debt a larger claim on the business than the ~$10.5 billion equity, and the Arbex purchase adds to it before deleveraging resumes. The November 5 report, with Arbex consolidated for the first time, is the next read on both.

Headline figures (approximate, October 2026): KMB shows revenue (ttm, continuing operations) ~$16.6 billion (flat YoY), operating margin ~19%, net income (ttm) ~$1.7 billion (EPS ~$5.07), p/e ~21x trailing, ~14x forward; SUZ shows revenue (ttm) ~R$47.8 billion, down ~13% year on year in the latest quarter, q2 2026 ~R$11.6 billion revenue, ~R$4.7 billion adjusted EBITDA, ~R$1.8 billion net income, net income (ttm) ~R$8.2 billion (~17% net margin), price to earnings ~6.8x trailing, ~5.8x forward.

KMB and SUZ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KMB and SUZ exposure against your real portfolio. It is not an investment adviser.